Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease
- 15 March 2010
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 68 (1), 28-36
- https://doi.org/10.1002/ana.22021
Abstract
Objective Peripheral neuropathy (PN) is thought to be coincidental in patients with idiopathic Parkinson disease (IPD). We sought to examine the prevalence of PN in a population of IPD patients and a potential relationship to levodopa use and fasting methylmalonic acid (MMA) levels. Methods In a prospective cohort study, IPD patients randomly selected from a comprehensive database were compared to control subjects regarding the presence and severity of PN using clinical and electrophysiological measures. IPD severity was determined using the Unified Parkinson's Disease Rating Scale (UPDRS). We determined the relation of levodopa use with serum levels of cobalamin, MMA, and homocysteine (Hcy). We also explored the association between presence and severity of PN and age, duration of IPD, cumulative levodopa dosing, cobalamin, MMA, and Hcy levels. Results Fifty-eight randomly selected IPD patients were compared to 58 age- and sex-matched controls. PN was present in 55% of IPD patients and 9% of controls. Patients with IPD had greater prevalence of PN and fasting MMA/Hcy levels than controls. IPD patients with PN were older and exhibited higher UPDRS scores, fasting MMA/Hcy levels, and cumulative levodopa exposure. PN severity in IPD subjects positively correlated with both levodopa exposure and MMA levels. Interpretation IPD patients have a higher prevalence of PN than controls. Although causality is not established, levodopa exposure is associated with MMA elevation and sensorimotor neuropathy in IPD patients. Cobalamin replacement concurrent with levodopa therapy should be considered to protect against development of PN in IPD patients. ANN NEUROL 2010;67:28–36Keywords
This publication has 26 references indexed in Scilit:
- Practice Parameter: Evaluation of distal symmetric polyneuropathy: Role of laboratory and genetic testing (an evidence-based review)Neurology, 2009
- Neuropathy as a potential complication of levodopa use in Parkinson's diseaseMovement Disorders, 2008
- Distal symmetric polyneuropathy: A definition for clinical researchNeurology, 2005
- Parkinsonism, premature menopause, and mitochondrial DNA polymerase γ mutations: clinical and molecular genetic studyThe Lancet, 2004
- Parkin disease: a phenotypic study of a large case seriesBrain, 2003
- Validation of the Toronto Clinical Scoring System for Diabetic PolyneuropathyDiabetes Care, 2002
- Homocysteine and Risk of Ischemic Heart Disease and StrokeJama-Journal Of The American Medical Association, 2002
- Peripheral neuropathy due to cobalamin deficiencyCurrent Treatment Options in Neurology, 2002
- Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's DiseaseNew England Journal of Medicine, 2002
- Variables influencing neuropathic endpointsNeurology, 1995